ASND N Stock Overview
A biopharmaceutical company, focuses on developing therapies for unmet medical needs. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Ascendis Pharma A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2,559.00 |
52 Week High | US$2,559.00 |
52 Week Low | US$2,090.00 |
Beta | 0.65 |
11 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | -17.59% |
5 Year Change | n/a |
Change since IPO | 274.12% |
Recent News & Updates
Recent updates
Shareholder Returns
ASND N | MX Biotechs | MX Market | |
---|---|---|---|
7D | 0% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how ASND N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how ASND N performed against the MX Market.
Price Volatility
ASND N volatility | |
---|---|
ASND N Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: ASND N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine ASND N's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 879 | Jan Mikkelsen | ascendispharma.com |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S Fundamentals Summary
ASND N fundamental statistics | |
---|---|
Market cap | Mex$150.90b |
Earnings (TTM) | -Mex$9.13b |
Revenue (TTM) | Mex$7.01b |
21.5x
P/S Ratio-16.5x
P/E RatioIs ASND N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ASND N income statement (TTM) | |
---|---|
Revenue | €327.43m |
Cost of Revenue | €49.69m |
Gross Profit | €277.74m |
Other Expenses | €704.23m |
Earnings | -€426.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -7.14 |
Gross Margin | 84.82% |
Net Profit Margin | -130.26% |
Debt/Equity Ratio | -810.4% |
How did ASND N perform over the long term?
See historical performance and comparison